About this episode

The episode features an interview with Anthony Durkacz discussing Quantum BioPharma's focus on innovative therapies for multiple sclerosis.

Disseminated on behalf of Quantum BioPharma, may include paid advertisements. AUSTIN, Texas, June 2, 2026 – via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The BioMedWire Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels. The BioMedWire Podcast delivers dynamic interviews with industry experts at the forefront of pharmaceutical and biotech advancement. The latest episode features Anthony Durkacz, Co-Founder and Executive Co-Chair of Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM), a biopharmaceutical company focused on advancing innovative therapies and technologies. To begin the interview, Durkacz outlined Quantum BioPharma’s primary focus on advancing its lead multiple sclerosis drug candidate, Lucid-MS. “Quantum BioPharma is focused on a drug candidate that is trying to address an issue that exists today for people that suffer from multiple sclerosis,” he said. “If you know anybody that has the disease, you will see that over time there is a progression where they begin…

People in this episode

Guest: Anthony Durkacz

Topics covered

• biopharmaceuticals
• multiple sclerosis
• drug development
• interviews
• healthcare innovation

Keywords

• Quantum BioPharma
• multiple sclerosis
• Lucid-MS
• biotech
• pharmaceutical advancement

Mentioned in this episode

Organizations: Quantum BioPharma Ltd., IBN, NASDAQ: QNTM, CSE: QNTM

Products: Lucid-MS

Places: Austin, Texas

More episodes of The BioMedWire Podcast

• How Advanced Drug Delivery Could Improve Existing Cancer Treatments · June 5, 2026 · 21 min
• How Advanced Drug Delivery Could Improve Existing Cancer Treatments [Video Edition] · June 5, 2026 · 21 min
• BioMedWire Podcast Featuring Anthony Durkacz, Executive Co-Chair of Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) · June 2, 2026 · 17 min
• CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities · May 15, 2026 · 20 min
• CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities [Video Edition] · May 15, 2026 · 20 min
• The Next Generation of the GLP-1 Revolution Is Already Underway · May 15, 2026 · 22 min

Explore listener stats, chart rankings, contacts and more on the The BioMedWire Podcast podcast page.